(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Which game do you cherish observing live? Vote! - 2Remain Cool and Solid: Top Summer Food sources for 2024
- 3Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- 4Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- 5Astounding Treehouses All over the Planet
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- Monetary Strengthening: Assuming Command over Your Cash
- Pick the Ideal Family Feline Variety for Your Home
- Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- Sixteen Kenyans missing in Russia after army recruitment
